THE GLOBAL CAMPAIGN TO HAVE ANTINEOPLASTONS A10 & AS2-1
APPROVED FOR THE TREATMENT OF CANCER.

JOIN THE FIGHT!  Submit your details and in coming weeks we'll let you know how you can help.

Your name (required)

Your email address (required)

  • Antineoplastons were discovered in 1967 by Dr Stanislaw Burzynski in Poland, the same year he graduated Medical School first in his class of 250 students at age 24.
  • Antineoplastons are synthetically produced peptides and amino acid derivatives designed to reprogram cancer cells. Antineoplaston A10 is the first naturally occurring antineoplaston substance in the human body to be chemically identified.
  • In 1977, Dr Burzynski opened his clinic in Houston, Texas after 7 years at Baylor College of Medicine.
  • Antineoplastons have been in official Food & Drug Administration (FDA) sanctioned clinical testing since 1993. In 2013, fourteen Phase II clinical trials have been successfully completed under the FDA's supervision.
  • Antineoplastons is the first and only cancer therapy in world medical history to cure a diffuse intrinsic pontine glioma (DIPG) brain tumor, thus also being the first group of new medications to ever demonstrate enough safety and efficacy within FDA-sanctioned clinical trials to graduate into the first-ever Phase 3 randomized study using a new medication for a DIPG.
  • In Japan, a medical research team at Kurume University in Fukuoka, Japan have conducted 27 years of independent clinical testing of Antineoplastons. This team designed their own dosages, schedules, and modalities, without any input from the inventor, ending in the first ever randomized clinical trials using Antineoplastons on humans. The randomized clinical trial was designed by the scientific community to eliminate anecdotal data and bias within a scientific study. Based on the Japanese studies of Antineoplastons, these medications are now a "proven" anti-cancer agent, and its results can no longer be considered anecdotal.
  • Antineoplastons are gentle medications—and there is no evidence that anyone has died from using them.
  • Some insurance companies have been told to pay for Antineoplaston treatment after losing lawsuits.
  • Dr Burzynski's clinic and research institute currently employs about 108 people, 18 of whom are M.D.'s and Ph.D.'s, Physician Assistants and Nurse Practitioners.
  • The National Cancer Institute has acknowledged the safety and efficacy of Antineoplastons in both an on-site visitation as well as via its website materials today.
  • Dr Stanislaw Burzynski has over 300 publications related to Antineoplastons, many of them peer-reviewed.
  • Over 100 independently-run Antineoplaston studies have been published, including the Japanese studies.

Our goal is to have Antineoplastons A10 and AS2-1 approved for the treatment of cancer.

Since the United States launched the "War On Cancer" and the rest of the western world followed suit, the rate of cancer deaths per capita have remained unchanged worldwide.

Yet, for over 35 years Antineoplastons have been administered to patients in a clinic in Houston, Texas. Since 1993, FDA-sanctioned clinical trials have been underway using Antineoplastons. Fourteen of these trials were successfully completed in 2012.

Within experimental FDA-sanctioned clinical trials, Antineoplastons are responsible for curing certain cancers never before cured in medical history.

Upon completion of fourteen Phase II FDA clinical trials in the United States, and 27 years of independently conducted and designed clinical trials in Japan—ending in the first successful randomized clinical trial showing double the survival rates in the Antineoplaston group—Antineoplastons still remain "unapproved" for market worldwide.

In January 2013, America's Food & Drug Administration placed a temporary hold on all new patients getting Antineoplastons.

It seems the only way that our global human family will have access to these ground-breaking and potentially life-saving medications is for the people of our world to take control and force regulatory agencies worldwide to allow these gentle cancer medications to be accessible.

The first condition Antineoplastons should be granted approval for is in childhood brain tumors and among them diffuse intrinsic brainstem glioma (DIPG). Not only do Antineoplastons hold the first and only cures in world medical history for this condition, but they are the first "new" medications to ever show enough safety and efficacy within FDA-sanctioned clinical trials to be granted permission for a Phase 3 randomized study for a DIPG.

After 35 years of the inventor, the supporting medical community, and his patients trying to convince the American government and regulatory agencies to be allowed to freely participate in the drug approval process within our so-called "Free Market", it has become apparent that seeking refuge in a non-American country to create a massive tourism industry for cancer patients may be inevitable.

Whether this fight is won in America, or won overseas, one thing is certain—the only way this fight can be won is if the majority of the world's population understands the problem, and understands what Antineoplastons are.

Our mission is to—first, make the world aware of these medications and the bureaucratic obstacles it faces—and second, to convince one or more of the world's regulatory agencies to adhere to their own ethical guidelines for drug approval, thus allowing Antineoplastons to be made available to the general public—unobstructed by market and government forces.

Our mission has just begun.

1. Fundraising:

In today's environment, few things can be accomplished without a lot of monetary capital. Our first goal is to raise as much money as possible to expand our message of "awareness" around this issue. Such messages will take the form of: National TV advertising, National magazine and newspaper advertising, and a basic public relations launch that will be ongoing.

Upon reaching larger numbers of subscribers to this organization, we will begin to continue fighting in the United States by holding massive nationwide rallies and cancer walks to further awareness and the goal of raising money for this cause.


2. Making Antineoplastons available to the public:

Unlike all other cancer research campaigns which rely 100% on awareness alone, we realize that awareness itself does not cure the disease. Medications such as Antineoplastons are what can lead to the cure of the disease of cancer. If the United States still refuses to allow Antineoplastons into its marketplace, we will then make sure another country will be properly funded to set up the proper channels for Antineoplastons to be approved for their marketplace. Another avenue would be simply opening up a massive Antineoplastons clinic allowing the cancer patients of the world to seek treatment using Antineoplastons.

Upon gaining either market approval—or the funding the construction of an Antineoplaston clinic overseas, our funds will then go to make sure everyone who cannot afford to travel overseas to receive Antineoplaston therapy—can do so by requesting money through this organization.

Either way, whether the market or its government's regulatory agencies want Antineoplastons available to its citizens or not—Antineoplastons are here to stay, and the members of our global human family deserve the right to have access to them.

It's time the bureaucratic paradigm of controlling cancer to sustain the marketplace—be upgraded to curing cancer, leaving Antineoplastons and cancer in the drawer next to the common infection and antibiotics.